ANCN Anchiano Therapeutics ADS

Anchiano to Hold Virtual Annual Meeting of Shareholders

Anchiano to Hold Virtual Annual Meeting of Shareholders

CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) as a virtual meeting due to the ongoing public health concerns related to the coronavirus (COVID-19) pandemic. The Annual Meeting will still be held on April 23, 2020 at 11:00 a.m. (Eastern Daylight Time).

As described in the proxy materials for the Annual Meeting (the “Proxy Materials”), shareholders as of the close of business on March 23, 2020, the record date, are entitled to participate in the Annual Meeting. Shareholders can participate in the Annual Meeting via the internet by visiting and entering the meeting number (280 326 067). Shareholders can also participate in the Annual Meeting by dialing 1-415-655-0003 in the United States, or 1-809-454-387 in Israel, and entering the identifying information described above. Shareholders will not be able to attend the Annual Meeting in person. We encourage shareholders to log into the website and access the webcast before the Annual Meeting’s start time.

All shareholders are encouraged to vote and submit their proxies in advance of the Annual Meeting by one of the methods described in the Proxy Materials. The proxy card previously distributed with the Proxy Materials will not be updated to reflect the change in meeting format and may continue to be used to vote shares in connection with the Annual Meeting. Shareholders who have previously sent in proxies do not need to take any further action.

About the Company

The Company is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel targeted therapies to treat cancer in areas of significant clinical need located in Cambridge, MA.  The Company is developing small-molecule pan-RAS inhibitors and inhibitors of PDE10 and the b-catenin pathway.  For more information on the Company, please visit

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to risks and uncertainties.  These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of the Company, including, without limitation, the risk factors and other matters set forth in its filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2019.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Company Contact:

Frank Haluska, M.D., Ph.D.

President and Chief Executive Officer

Investor Contact:

Ashley R. Robinson

Managing Director

LifeSci Advisors, LLC

617-430-7577

EN
17/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Anchiano Therapeutics ADS

 PRESS RELEASE

Anchiano Announces Shareholder Approval of the Merger with Chemomab an...

Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing Anchiano shareholders approve all resolutions at shareholder meeting The merged company is expected to receive approximate gross proceeds from the private financing of $45.5 million, which will be used to advance the Chemomab pipeline TEL-AVIV, Israel, March 15, 2021 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”; Nasdaq: ANCN) and (“Chemomab”), a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrosis-related diseas...

 PRESS RELEASE

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merg...

Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel CAMBRIDGE, Mass. and TEL-AVIV, Israel, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (“Anchiano”) (Nasdaq: ANCN), a...

 PRESS RELEASE

Anchiano Appoints Stan Polovets as Chairman of the Board

Anchiano Appoints Stan Polovets as Chairman of the Board CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the board of Anchiano in April 2020. He previously served as CEO of AAR, a private equity firm with a global energy portfolio valued in excess of $25 billion, and represented TNK in its merger with BP to form one of the world’s largest oil companies and in the eventual sale of the merged company TNK-BP for $55 bill...

 PRESS RELEASE

Anchiano Therapeutics Reports First Quarter 2020 Financial Results

Anchiano Therapeutics Reports First Quarter 2020 Financial Results CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies, today reported financial results for its first quarter ended March 31, 2020. “We have been very active this quarter and are continuing to transform as a company. We continue to focus on developing our targeted pan-mutant RAS...

 PRESS RELEASE

Anchiano Appoints Steve DiPalma as Chief Financial Officer

Anchiano Appoints Steve DiPalma as Chief Financial Officer CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities. Mr. Burgin will remain in the position of Chief Operating Officer until the final closure of...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch